A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Emicerfont (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 14 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2008 Results are expected in the second half of 2008 according to Neurocrine media release.